- Home
- VSTD vs BLRX Comparison
VSTD vs BLRX Comparison
Compare VSTD & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | BLRX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 17.1M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | VSTD | BLRX |
|---|---|---|
| Price | $0.47 | $3.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 422.8K | 26.9K |
| Earning Date | 11-14-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,902,861.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.39 | N/A |
| 52 Week Low | $0.40 | $2.30 |
| 52 Week High | $5.63 | $14.70 |
Technical Indicators
Market Signals| Indicator | VSTD | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.18 |
| Support Level | N/A | $3.12 |
| Resistance Level | N/A | $3.86 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 35.38 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc. Class A Common Stock
Vestand Inc is a California-based Vestand is a fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.